Universal reference book for medicines
Name of the preparation: PROSTAPLANT (PROSTAPLANT В® )

Active substance: Serenoa repens

Type: Phytomedication used for functional disorders of urination associated with benign prostatic hyperplasia

Manufacturer: Dr.
WILLMAR SCHWABE (Germany) manufactured by RPSCHERER (Germany)
Composition, form of production and packaging
Capsules of green color, gelatinous, oval, with a seam; the contents of capsules - the mass of oily consistency from light brown to dark brown color, with a characteristic odor.
1 caps.

dry extract of fruits serenoi creeping (10-14.3: 1) 320 mg

Excipients: glycerol, gelatin polysuccinate, iron oxide yellow oxide (E172), iron oxide black oxide (E 172), blue dye patented (E131).

Extractant: ethanol 90%.

10 pieces.
- blisters (3) - packs of cardboard.
10 pieces.
- blisters (6) - packs of cardboard.
20 pcs.
- blisters (3) - packs of cardboard.
20 pcs.
- blisters (6) - packs of cardboard.

Description of the drug approved by the manufacturer for the printed edition of 2016.


A preparation of vegetable origin, used in the treatment of benign prostatic hyperplasia.
It has antiandrogenic, anti-inflammatory and anti-edematous effects selectively on prostate tissue.
The mechanism of antiandrogenic action is due to inhibition of the activity of 5-alpha-reductase (as a result of which the transformation of testosterone into dihydrotestosterone is broken).
Under the influence of this enzyme, the testosterone entering the prostate gland turns into an active form - dihydrotestosterone. The prostaplant prevents the formation of a dihydrotestosterone-receptor complex, its penetration into the nucleus of the cell, and subsequent inducing of protein synthesis. As a result of this action, the process of proliferative changes in the tissues of the prostate gland is inhibited. Prostaplant does not affect the levels of testosterone, FSH and LH in the blood plasma in men.
Anti-inflammatory and anti-edema effect of the drug is due to inhibition of enzymes - cyclooxygenase and 5-lipoxygenase.

Prostaplant reduces capillary permeability and vascular stasis, reduces edema and inflammation of the prostate, thus eliminating compression on the neck of the bladder and urethra, improving the dynamics of the urinary tract.

The use of the drug helps to reduce specific symptoms of benign prostatic hyperplasia (dysuria, pollakuriya, nocturia, decreased volume and strength of urination, incomplete emptying of the bladder, pain and a sense of tension in the perineum at the I and II stages of the disease).

Prostaplant does not reduce potency, does not affect the level of prostate-specific antigen (PSA) in the blood plasma.


The action of the drug Prostaplant is the cumulative effect of its components, therefore carrying out kinetic studies is not possible.


- Disorders of urination with benign prostatic hyperplasia of the I and II stages.


The drug is taken orally 1 capsule 1 time / day.
Capsules should be swallowed, not liquid and squeezed with a small amount of liquid.
Duration of treatment - at least 3 months.

The optimal scheme and repeated courses of treatment are established and appointed by the doctor individually in each case on the basis of a diagnostic examination.


From the digestive system: rarely - nausea, heartburn, gastralgia (especially when taking the drug on an empty stomach).

Other: allergic reactions are possible.


- Hypersensitivity to the components of the drug.


With caution should prescribe the drug to patients with a history of gastrointestinal disease.

Before using the drug, you should make sure that the disease is benign.


Until now, there have been no reports of overdose of Prostaplant.


Clinically significant drug interaction of the drug Prostaplant was not detected.


The drug is approved for use as a means of OTC.


The drug should be stored out of reach of children at a temperature of no higher than 30 В° C.
Shelf life - 5 years.
Alphabetical index of medicines:
A  B  V  G  D  E  J
Z  I  Y  K  L  M  N
O  P  R  S  T  U  F
H  C  CH  SH  E  U  Y

Privacy policy:
Copyright 2009 - 2017. Universal reference book of medicines. All rights reserved.
When using site materials, an active hyperlink is required!